From Wikipedia, the free encyclopedia
Clinical data
Trade namesRevcovi
Other nameselapegademase-lvlr
License data
Routes of
ATC code
Legal status
Legal status
CAS Number

Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.[1]

It is a recombinant enzyme[2] that is administered weekly by intramuscular injection.[3]

Elapegademase may interact with PEGylated drugs.[3]

Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018.[4][5][6] Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.[7]


  1. ^ Skidmore-Roth L (2022). "Elapegademase". Mosby's 2023 Nursing Drug Reference. Elsevier Health Sciences. p. 429. ISBN 978-0-323-93330-8.
  2. ^ "Elapegademase: Drug Information". www.uptodate.com. Retrieved 28 March 2019.
  3. ^ a b "LexiComp: Elapegademase-lvlr". LexiComp. Retrieved 28 March 2019.
  4. ^ "Drug Approval Package: Revcovi". U.S. Food and Drug Administration (FDA). 7 November 2018. Retrieved 26 December 2019.
  5. ^ "Elapegademase-lvlr Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 26 December 2019.
  6. ^ "Drug Trial Snapshot: Revcovi". U.S. Food and Drug Administration (FDA). 5 October 2018. Retrieved 26 December 2019.
  7. ^ "Elapegademase - Leadiant Biosciences". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 March 2019.

External links[edit]

  • "Elapegademase". Drug Information Portal. U.S. National Library of Medicine.